With the exception of first-line treatment guidelines for ALK-positive ALCL, there is currently no standard of care for the treatment of PTCL and no approved agents for first-line treatment (NCCN, 2014). The gene discussed is ALK; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.